Get the Stockscreener App
1,078.78
1.37%
14.63
After Hours:
1086.00
7.22
+0.67%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,078.78, with a volume of 2.64M.
It is up +1.37% in the last 24 hours and up +11.98% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,064.15
Open:
$1059.5
24h Volume:
2.64M
Relative Volume:
0.87
Market Cap:
$961.99B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
38.83
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-0.38%
1M Performance:
+11.98%
6M Performance:
+4.38%
1Y Performance:
+43.69%
1-Day Range:
$1,053.51
$1,093.28
1-Week Range:
$1,052.15
$1,149.10
52-Week Range:
$623.78
$1,149.10
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,078.78 | 948.95B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
223.24 | 536.54B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
217.13 | 380.57B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
114.70 | 285.64B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.66 | 273.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly Weight Loss Boom Reshapes Healthcare Growth Story - Kalkine Media
Law Firm Asks US to Investigate Eli Lilly’s Drug Discount Policy - Bloomberg Law News
Prediction: Eli Lilly Will Be Worth More Than SpaceX in 2 Years - AOL.com
Eli Lilly (LLY) Cuts German Investment Plans Amid Focus on U.S. Market - GuruFocus
Eli Lilly scoops up Houston biotech startup in $300 million deal - InnovationMap
Eli Lilly & Co. stock (US5324571083): Indiana manufacturing push and acquisition drive keep focus on - AD HOC NEWS
Lilly cuts Germany investment plan in half over healthcare reforms By Investing.com - Investing.com Australia
Prediction: Eli Lilly Will Be Worth More Than SpaceX in 2 Years - The Motley Fool
Lilly, BioNTech Warn German Health Reforms Could Hurt Investment - Bloomberg.com
Where Will Eli Lilly Stock be In 2028? - 24/7 Wall St.
Lilly enters $1.9B kidney disease deal for Ascidian’s exon editors - BioWorld News
Lilly: Drug shows promise against early lung cancer with rare biomarker - Indianapolis Business Journal
‘Expect More Acquisitions,’ Says Eli Lilly’s (LLY) Top Dealmaker - TipRanks
Eli Lilly (LLY) Forges $1.9 Billion Partnership with Ascidian for Kidney Disease Therapies - parameter.io
Eli Lilly (LLY) Partners with Ascidian in $1.9 Billion Kidney Disease Technology Collaboration - MoneyCheck
Eli Lilly (LLY) Secures $1.9 Billion Partnership With Ascidian for Kidney Disease Therapies - Blockonomi
Legend Biotech emerged as a rare market winner - statnews.com
Eli Lilly (LLY) Stock Signs $1.9B Kidney Disease Deal With Ascidian Therapeutics - CoinCentral
Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs - Reuters
China's Haisco Pharma inks $2.9 B deal with Eli Lilly focusing on multiple therapeutic areas - BioSpectrum Asia
Goldman Sachs Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,283 - Moomoo
Eli Lilly (LLY) Expands Acquisition Strategy with $10 Billion De - GuruFocus
Lilly, Ascidian Strike RNA-Editing Pact For Up to $1.9 Billion - Bloomberg.com
Eli Lilly Unleashes Obesity Windfall on Aggressive Biotech Spree - streamlinefeed.co.ke
Eli Lilly inks deal worth up to $1.9B with Boston biotech for kidney disease work - The Business Journals
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck - BioSpace
Illinois hospitals urge Pritzker to quickly sign bill before Eli Lilly cuts off drug discounts - Crain's Chicago Business
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out - The Motley Fool
Eli Lilly Stock Surges 18 Percent Following Strong First Quarter Results - asatunews.co.id
Hanmi Pharm lands $1.2 bn Lilly licensing deal for gut disorder drug - KED Global
Eli Lilly Threatens to Pull Hospital Drug Discounts Over Data - asatunews.co.id
Eli Lilly and Co stock (US5324571083): shares ease after recent gains as investors digest Q1 momentu - AD HOC NEWS
Eli Lilly (LLY) Halts 340B Discounts for Non-Compliant Hospitals - GuruFocus
Eli Lilly issues data sharing ultimatum to 340B hospitals - BioPharma Dive
Hanmi, Haisco win billion-dollar partnerships with Eli Lilly - BioWorld News
Eli Lilly (LLY) Showcases Key Data at European Hematology Association Meeting - GuruFocus
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage - MarketBeat
Eli Lilly Expands Obesity Medicine Insurance Coverage Nationally - HarianBasis.co
Eli Lilly and Company’s (LLY) Foundayo and Zepbound Set To Be Covered for Millions of Americans - Insider Monkey
Is Eli Lilly and Company (LLY) Expanding Into Next-Gen Vaccines With $1.55B Acquisition? - Insider Monkey
Lilly to present hematology data at EHA meeting in June - Investing.com
Eli Lilly Reportedly Shuts HK Branch, Lays Off 50 Employees - AASTOCKS.com
Hanmi Pharmaceutical jumps on Eli Lilly tech transfer deal in South KoreaCHOSUNBIZ - Chosunbiz
Korea Investment & Securities lifts Hanmi target after Lilly tech dealCHOSUNBIZ - Chosunbiz
Eli Lilly scores a first in major pharma milestone - thestreet.com
Novo Nordisk A/S Stock (NVO) Closed Down by 3.41% on Jun 1: Key Drivers Unveiled - TradingKey
Selling pressure pushes Eli Lilly stock lower in today's trading - Traders Union
Eli Lilly (LLY) Expands Licensing Agreement with Camurus for Car - GuruFocus
These 8 Words From Eli Lilly's CEO Have Wall Street Turning Bullish - Yahoo Finance
Eli Lilly Reports 56 Percent Revenue Surge Fueled by Diabetes and Weight Loss Drugs - asatunews.co.id
Eli Lilly (LLY) Expands Collaboration with Camurus on Amylin Rec - GuruFocus
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):